Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma: Open Label Prospective Randomized Clinical Trial

NCT04998552 is registered in ClinicalTrials.gov with Capital Health System, Inc as lead sponsor.

NCT NCT04998552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04998552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma: Open Label Prospective Randomized Clinical Trial
Lead sponsor
Capital Health System, Inc
Phase
Not applicable
Overall status
Recruiting
Start date
June 22, 2021
Completion date
June 22, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas adenocarcinoma